SPStephanie S. Philip

Stephanie S. Philip

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephanie S. Philip has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Charles D. Fraser

    Texas Center for Pediatric and Congenital Heart Disease Dell Medical School at the University of Texas at Austin Austin Texas USA

    2 shared publications
  • Chesney Castleberry

    Dell Children's Hospital Austin Texas USA

    2 shared publications
  • Alexandra Lamari-Fisher

    Department of Pediatrics, Texas Center for Pediatric and Congenital Heart Disease, University of Texas Dell Medical School/Dell Children’s Medical Center, Austin, TX, USA

    1 shared publication
  • Andrew Well

    Department of Cardiac Surgery, Division of Pediatric Cardiac Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA and Pediatric Heart Institute, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, USA

    1 shared publication
  • Anne Halpin

    Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Alberta Precision Laboratories, Edmonton, Alberta, Canada; Canadian Donation and Transplantation Research Program, Alberta Transplant Institute, University of Alberta, Edmonton, Alberta, Canada

    1 shared publication
  • Austin F. Lee

    Department of Population and Quantitative Health Sciences University of Massachusetts Medical School Worcester Massachusetts USA

    1 shared publication

Latest Publications

  • Advancing ABO-histocompatibility: Impact of multiplexed ABO antibody immunoassay to increase precision in pediatric heart transplantation

    by Lauren D. Glass, Cathi Murphey, Chesney D. Castleberry, Stephanie S. Philip, Anne Halpin, Lori J. West


  • Pediatric Marfan Syndrome and Heart Transplantation: Insights From the PHIS Database

    by Stephanie S. Philip, Hugo R. Martinez, Matthew F. Mikulski, Andrew Well, Sagar Jani, Lauren Glass, Charles D. Fraser, Chesney Castleberry

    Background: Marfan syndrome (MFS) is a connective tissue disorder associated with significant cardiovascular complications, including heart failure. Orthotopic heart transplantation (OHT) is considered controversial in this population due to concerns about post‐transplant aortic complications, particularly in children. Methods: We conducted a retrospective review of the Pediatric Health Information System (PHIS) database to identify patients under 18 years of age with a diagnosis of MFS who underwent OHT between 2004 and 2024. Patients were propensity matched (3:1) to non‐MFS OHT recipients. Outcomes included graft failure, aortic events, and re‐transplant‐free survival. Results: Ten pediatric MFS patients were identified among 5493 OHT recipients. The median age at OHT was 12.5 years. Over a median follow‐up of 3.73 years, no in‐hospital mortalities or repeat transplants were observed; two patients experienced rejection, and one developed aortic root dilation without requiring intervention. Propensity‐matched analysis showed no significant differences in rejection, aortic events, or transplant‐free survival between MFS and non‐MFS cohorts. Conclusion: Though rare, pediatric MFS patients undergoing OHT demonstrated excellent short‐term outcomes with no MFS‐related surgical complications. These findings challenge current exclusionary practices and support further research into long‐term outcomes.


  • Decision making in anomalous aortic origin of a coronary artery

    by Hitesh Agrawal, Alexandra Lamari-Fisher, Keren Hasbani, Stephanie Philip, Charles D. Fraser, Carlos M. Mery

    There are many uncertainties surrounding anomalous aortic origin of a coronary artery (AAOCA) including the pathophysiology of sudden cardiac death, how to best risk stratify patients, how to best evaluate patients, who would benefit from exercise restriction, who should undergo surgical intervention and which operation to perform. The goal of this review is to provide a comprehensive, but succinct overview of AAOCA to help clinicians with the difficult task of navigating optimal evaluation and treatment of an individual patient with AAOCA. : Beginning in year 2012, some of our authors proposed an integrated, multi-disciplinary working group which has become the standard management strategy for patients diagnosed with AAOCA. A multi-disciplinary team, with a focus on shared decision-making with the patients/families is likely necessary to optimize outcomes. Long-term follow up and research is needed to improve our understanding of AAOCA.


  • Impact of a targeted volume‐increase nutrition guideline on growth and body mass index in premature infants: A retrospective review

    by Stephanie S. Philip, Sarah E. Davenport, Javed Mannan, Heather O. White, Austin F. Lee, Lawrence M. Rhein

    Background: The negative impact of disproportionate growth in premature infants is well documented, but optimal nutrition practices needed to prevent an unhealthy body mass index (BMI) remain unclear.Methods: An evidence‐based, volume‐increase guideline that advanced feeding volumes from 150–160 to 170–180 ml/kg/day between the postmenstrual age (PMA) of 31 0/7 and 34 0/7 weeks was implemented in October 2017 for infants born at ≤32 0/7 weeks’ gestational age. Data were collected on 262 infants’ weight and length at birth and at discharge for 20 months before and 21 months after guideline implementation, and retrospective analysis was conducted to determine disproportionate growth by comparing BMIs (in g/cm2) at birth and at discharge. Changes in infants’ body habitus were determined through bivariate analysis of weight and length z‐scores from the Fenton growth curve.Results: Implementation of a targeted volume nutrition guideline resulted in fewer infants with growth failure, defined as weight P = .06) at discharge. Infants who received treatment according to the targeted nutrition guideline had a statistically significant reduction in disproportionately low BMI (8.6% vs 2.5%; P = .0380) and an increase in disproportionately high BMIs (4.3% vs 12.3%; P = .025). There was minor change in the percentage of disproportionately large infants who received the guidelines from birth to discharge (11.5% vs 12.3%).Conclusions: A targeted volume‐increase nutrition guideline may prevent growth failure, with some effects on disproportionate growth in preterm infants born at ≤32 0/7 weeks’ gestational age.